CAJ | 학술논문

目的：研究恩替卡韦辅助治疗乙肝肝硬化失代偿期的临床效果。方法随机选取2012年4月—2014年4月该院收治的70例乙型肝炎肝硬化失代偿期患者为研究对象，将其随机分为观察组和对照组，对照组采用常规对症治疗，观察组在常规治疗基础上，采用恩替卡韦辅助治疗，比较两组患者治疗效果。结果观察组HBV-DNA转阴率明显高于对照组，且死亡率比对照组低，差异有统计学意义（χ2=8.548，P＜0.05）。结论恩替卡韦辅助治疗乙型肝炎引起的肝硬化失代偿期患者，能有效降低肝硬化失代偿期死亡率，疗效显著，具有临床推广价值。
목적：연구은체잡위보조치료을간간경화실대상기적림상효과。방법수궤선취2012년4월—2014년4월해원수치적70례을형간염간경화실대상기환자위연구대상，장기수궤분위관찰조화대조조，대조조채용상규대증치료，관찰조재상규치료기출상，채용은체잡위보조치료，비교량조환자치료효과。결과관찰조HBV-DNA전음솔명현고우대조조，차사망솔비대조조저，차이유통계학의의（χ2=8.548，P＜0.05）。결론은체잡위보조치료을형간염인기적간경화실대상기환자，능유효강저간경화실대상기사망솔，료효현저，구유림상추엄개치。
Objective To study the clinical effect of entecavir treatment of hepatitis B decompensated liver cirrhosis. Methods Atotal of 2012 from April 2014 4 months in our hospital from 58 cases of hepatitis B cirrhosis decompensated pa-tients as the research object, randomly divided into observation group and control group, control group was treated with con-ventional symptomatic treatment, observation group in the conventional treatment on the basis of using en entecavir adjuvant therapy, compared two groups of patients with therapeutic effect. Results Observation group HBV-DNA negative rate was significantly higher than that of the control group, the difference is statistically significant(χ2=8.548, P<0.05). Conclusion EN entecavir adjuvant therapy for hepatitis B caused by cirrhosis decompensated patients, can effectively reduce the cirrho-sis decompensation stage mortality and significant effect, with clinical value.